Literature DB >> 40649

The influence of cerebral 5-hydroxytryptamine on catalepsy induced by brain-amine depleting neuroleptics or by cholinomimetics.

L D Fuenmayor, M Vogt.   

Abstract

1 Catalepsy was produced in rats and mice by the subcutaneous injection of either tetrabenazine or the butyrophenone U-32,802A (4'-fluoro-4-{[4-(p-fluorophenyl)-3-cyclohexen-1-yl]amino} butyrophenone hydrochloride). Catalepsy was evaluated by the duration of total immobility on a vertical grid.2 Pretreatment with p-chlorophenylalanine (PCPA) reduced the intensity of catalepsy by 50% or more, whereas its time course remained the same.3 5-Hydroxytryptophan (5-HTP), 10 mg/kg, enhanced the catalepsy induced by U-32,802A or tetrabenazine, provided it was administered soon (45 min) after the neuroleptic; injections at 90 min had no effect. Otherwise untreated rats given this dose of 5-HTP behaved normally on the grid.4 The anticataleptic effect of PCPA was reversed by 5-HTP.5 Measurable changes in 5-hydroxytryptamine (5-HT) metabolism in the rat forebrain accompanied the modification of catalepsy by 5-HTP and PCPA.6 Methysergide (5 mg/kg) given 30 min before the neuroleptics to either mice or rats reduced the catalepsy, assessed 2.5 h after the methysergide. It also prevented the increase in neuroleptic-induced catalepsy following 5-HTP, 10 mg/kg.7 Tryptophan, like 5-HTP, increased the catalepsy seen in mice after U-32,802A and tetrabenazine, and increased the production of 5-hydroxyindol-3-ylacetic acid in the forebrain.8 In the rat, intracerebroventricular injection of physostigmine produced catalepsy which was not modified by methysergide or PCPA but was abolished by atropine. Similarly, in the mouse, catalepsy induced by the subcutaneous injection of pilocarpine was abolished by atropine but not affected by either methysergide or 5-HTP.9 Atropine greatly reduced the catalepsy induced by U-32,802A and tetrabenazine but lowered striatal homovanillic acid (HVA) only after U-32,802A. D,L-DOPA, 20 mg/kg, diminished the cataleptogenic effect of both neuroleptics and raised striatal HVA.10 The results support the view that there is a facilitating or permissive action of 5-HT-containing neurones on neuroleptic-induced catalepsy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 40649      PMCID: PMC2043889          DOI: 10.1111/j.1476-5381.1979.tb08681.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Differential effects of serotonin on turning and sterotypy induced by apomorphine.

Authors:  R J Baldessarini; T T Amatruda; F F Griffith; S Gerson
Journal:  Brain Res       Date:  1975-07-25       Impact factor: 3.252

2.  Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy.

Authors:  J Maj; E Mogilnicka; B Przewlocka
Journal:  Pharmacol Biochem Behav       Date:  1975 Jan-Feb       Impact factor: 3.533

3.  Behaviour of cats after intraventricular injections of eserine and DFP.

Authors:  W FELDBERG; S L SHERWOOD
Journal:  J Physiol       Date:  1954-09-28       Impact factor: 5.182

4.  Serotonergic involvement with neuroleptic catalepsy.

Authors:  B Costall; D H Fortune; R J Naylor; C D Mardsen; C Pycock
Journal:  Neuropharmacology       Date:  1975-11       Impact factor: 5.250

Review 5.  Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

Authors:  O Hornykiewicz
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

6.  Role of 5-HT in the action of some drugs affecting extrapyramidal system.

Authors:  W Gumulka; W Kostowski; A Czlonkowski
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

7.  Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine.

Authors:  W Kostowski; W Gumulka; A Cxlonkowski
Journal:  Brain Res       Date:  1972-12-24       Impact factor: 3.252

8.  Catalepsy, sedation and hypothermia induced by alpha-methyl-p-tyrosine in the rat. An ideal tool for screening of drugs active on central catecholaminergic receptors.

Authors:  R Papeschi; A Randrup
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1973-05

9.  Animal model of depression. III. Mechanism of action of tetrabenazine.

Authors:  K H Tachiki; A Takagi; T Tateishi; A Kido; K Nishiwaki; E Nakamura; H Nagayama; R Takahashi
Journal:  Biol Psychiatry       Date:  1978-08       Impact factor: 13.382

10.  Effects of drugs acting on cerebral 5-hydroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice.

Authors:  J A Milson; C J Pycock
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

View more
  6 in total

Review 1.  5-HT2 antagonism and EPS benefits: is there a causal connection?

Authors:  S Kapur
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy.

Authors:  M L Wadenberg; S Ahlenius
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  A role for 5-hydroxytryptamine in the GABA-mimetic potentiation of alpha-flupenthixol-induced catalepsy in the rat.

Authors:  J A Davies; J Williams
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

4.  Antagonism by cholinomimetic drugs of the turning induced by intrastriatal pirenzepine in mice.

Authors:  P Worms; K Biziere
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Effect of metergoline, fenfluramine, and 8-OHDPAT on catalepsy induced by haloperidol or morphine.

Authors:  C L Broekkamp; S K Oosterloo; H H Berendsen; A M van Delft
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

Review 6.  d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.

Authors:  Danilo De Gregorio; Stefano Comai; Luca Posa; Gabriella Gobbi
Journal:  Int J Mol Sci       Date:  2016-11-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.